Brief: Aura Biosciences Reports Q2 Net Loss $13.5 Million
11/08/2022 21:51
Aug 11 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES CLINICAL DEVELOPMENT AND OPERATIONAL HIGHLIGHTS
* AURA BIOSCIENCES INC - ON TRACK TO INITIATE PIVOTAL TRIAL
IN
EARLY-STAGE CHOROIDAL MELANOMA IN Q4 2022
* AURA BIOSCIENCES INC - NET LOSS FOR THE THREE MONTHS ENDED
JUNE
30, 2022 WAS $13.5 MILLION
Source text for Eikon: ID:nBw13JRFxa
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs